Nurix plans to advance BTK degrader asset for chronic lymphocytic leukemia
by
Contributor since / Followers
Contributor since / Followers
2 days ago
- Nurix Therapeutics (NASDAQ:NRIX) will begin trials later this year for its experimental BTK degrader NX-5948 in chronic lymphocytic leukemia.
- The company is already conducting a phase 1b trial of the candidate for B-cell malignancies.
- Nurix added it is considering filing